By integrating preclinical insights on drug-tolerant persister cells with late-phase clinical data, this article outlines a future for <i>EGFR</i>-mutant NSCLC management defined by precision sequencing and the proactive mitigation of molecular resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.